Literature DB >> 26085207

Targeting signaling factors for degradation, an emerging mechanism for TRAF functions.

Xiao-Dong Yang1, Shao-Cong Sun2,3.   

Abstract

Tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) form a family of proteins that are best known as signaling adapters of TNFRs. However, emerging evidence suggests that TRAF proteins, particularly TRAF2 and TRAF3, also regulate signal transduction by controlling the fate of intracellular signaling factors. A well-recognized function of TRAF2 and TRAF3 in this aspect is to mediate ubiquitin-dependent degradation of nuclear factor-κB (NF-κB)-inducing kinase (NIK), an action required for the control of NIK-regulated non-canonical NF-κB signaling pathway. TRAF2 and TRAF3 form a complex with the E3 ubiquitin ligase cIAP (cIAP1 or cIAP2), in which TRAF3 serves as the NIK-binding adapter. Recent evidence suggests that the cIAP-TRAF2-TRAF3 E3 complex also targets additional signaling factors for ubiquitin-dependent degradation, thereby regulating important aspects of immune and inflammatory responses. This review provides both historical aspects and new insights into the signaling functions of this ubiquitination system.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NIK; TRAF2; TRAF3; cIAP; inflammation; non-canonical NF-κB

Mesh:

Substances:

Year:  2015        PMID: 26085207      PMCID: PMC4473799          DOI: 10.1111/imr.12311

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  134 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 2.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

3.  A fourth IkappaB protein within the NF-kappaB signaling module.

Authors:  Soumen Basak; Hana Kim; Jeffrey D Kearns; Vinay Tergaonkar; Ellen O'Dea; Shannon L Werner; Chris A Benedict; Carl F Ware; Gourisankar Ghosh; Inder M Verma; Alexander Hoffmann
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

4.  Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.

Authors:  Olivier Manches; Melissa Victoria Fernandez; Joel Plumas; Laurence Chaperot; Nina Bhardwaj
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-09       Impact factor: 11.205

5.  IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors.

Authors:  Hélène Authier; Katy Billot; Emmanuel Derudder; Didier Bordereaux; Pierre Rivière; Sylvie Rodrigues-Ferreira; Clara Nahmias; Véronique Baud
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

Review 6.  The noncanonical NF-κB pathway.

Authors:  Shao-Cong Sun
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 7.  Expanding role of ubiquitination in NF-κB signaling.

Authors:  Siqi Liu; Zhijian J Chen
Journal:  Cell Res       Date:  2010-12-07       Impact factor: 25.617

8.  Control of canonical NF-kappaB activation through the NIK-IKK complex pathway.

Authors:  Brian Zarnegar; Soh Yamazaki; Jeannie Q He; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

Review 9.  Tumour-associated macrophages and cancer.

Authors:  Jenny Cook; Thorsten Hagemann
Journal:  Curr Opin Pharmacol       Date:  2013-06-15       Impact factor: 5.547

10.  TRAF2 is an NF-κB-activating oncogene in epithelial cancers.

Authors:  R R Shen; A Y Zhou; E Kim; J T O'Connell; D Hagerstrand; R Beroukhim; W C Hahn
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more
  46 in total

1.  sNASP inhibits TLR signaling to regulate immune response in sepsis.

Authors:  Feng-Ming Yang; Yong Zuo; Wei Zhou; Chuan Xia; Bumsuk Hahm; Mark Sullivan; Jinke Cheng; Hui-Ming Chang; Edward Th Yeh
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

2.  TRAF3 Modulation: Novel Mechanism for the Anti-inflammatory Effects of the Vitamin D Receptor Agonist Paricalcitol in Renal Disease.

Authors:  Sandra Rayego-Mateos; Jose Luis Morgado-Pascual; José Manuel Valdivielso; Ana Belén Sanz; Enrique Bosch-Panadero; Raúl R Rodrigues-Díez; Jesús Egido; Alberto Ortiz; Emilio González-Parra; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2020-07-06       Impact factor: 10.121

3.  Rh-IFN-α attenuates neuroinflammation and improves neurological function by inhibiting NF-κB through JAK1-STAT1/TRAF3 pathway in an experimental GMH rat model.

Authors:  Peng Li; Gang Zhao; Yan Ding; Tianyi Wang; Jerry Flores; Umut Ocak; Pei Wu; Tongyu Zhang; Jun Mo; John H Zhang; Jiping Tang
Journal:  Brain Behav Immun       Date:  2019-01-31       Impact factor: 7.217

4.  The RNFT2/IL-3Rα axis regulates IL-3 signaling and innate immunity.

Authors:  Yao Tong; Travis B Lear; John Evankovich; Yanwen Chen; James D Londino; Michael M Myerburg; Yingze Zhang; Iulia D Popescu; John F McDyer; Bryan J McVerry; Karina C Lockwood; Michael J Jurczak; Yuan Liu; Bill B Chen
Journal:  JCI Insight       Date:  2020-02-13

5.  RNA sensor LGP2 inhibits TRAF ubiquitin ligase to negatively regulate innate immune signaling.

Authors:  Jean-Patrick Parisien; Jessica J Lenoir; Roli Mandhana; Kenny R Rodriguez; Kenin Qian; Annie M Bruns; Curt M Horvath
Journal:  EMBO Rep       Date:  2018-04-16       Impact factor: 8.807

6.  Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma.

Authors:  Yock Ping Chow; Lu Ping Tan; San Jiun Chai; Norazlin Abdul Aziz; Siew Woh Choo; Paul Vey Hong Lim; Rajadurai Pathmanathan; Noor Kaslina Mohd Kornain; Chee Lun Lum; Kin Choo Pua; Yoke Yeow Yap; Tee Yong Tan; Soo Hwang Teo; Alan Soo-Beng Khoo; Vyomesh Patel
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

7.  Etanercept as a TNF-alpha inhibitor depresses experimental retinal neovascularization.

Authors:  Yixuan Yao; Yujuan Cai; Ailing Sui; Yiyun Yao; Ting Su; Yanji Zhu; Bing Xie; Xi Shen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-10-12       Impact factor: 3.117

8.  Progranulin Is Positively Associated with Intervertebral Disc Degeneration by Interaction with IL-10 and IL-17 Through TNF Pathways.

Authors:  Shaoyi Wang; Jianlu Wei; Yuchen Fan; Hong Ding; Huichao Tian; Xiaocong Zhou; Lei Cheng
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

9.  TRAF molecules in inflammation and inflammatory diseases.

Authors:  Almin I Lalani; Sining Zhu; Samantha Gokhale; Juan Jin; Ping Xie
Journal:  Curr Pharmacol Rep       Date:  2017-12-20

Review 10.  Structural feature of TRAFs, their related human diseases and therapeutic intervention.

Authors:  Hyun Ho Park
Journal:  Arch Pharm Res       Date:  2021-05-10       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.